Avid Bioservices Inc (CDMO)

[volgoat]

Efforts to combine bavituximab with docetaxel as a treatment for patients with stage IIIb/IV nonsquamous non–small cell lung cancer (NSCLC) faltered earlier this year when the phase III SUNRISE trial was halted after a futility analysis, according to Peregrine Pharmaceuticals, the company developing the drug. - See more at: http://www.onclive.com/web-exclusives/emerging-immunotherapy-target-in-spotlight-at-wistar?p=2#sthash.ApbILphB.dpuf